Does FDA's Elepsia CRL Signal Broader Compliance Woes For Sun Spin-off?

Shares of Sun Pharmaceutical Industries Ltd were dented on Indian bourses after investors appeared concerned that the US FDA's decision to rescind a previous approval for its R&D arm's new drug application (NDA) for Elepsia XR (levetiracetam extended-release tablets) implied more than met the eye.

Shares of Sun Pharmaceutical Industries Ltd were dented on Indian bourses after investors appeared concerned that the US FDA's decision to rescind a previous approval for its R&D arm's new drug application (NDA) for Elepsia XR (levetiracetam extended-release tablets) implied more than met the eye.

Sun Pharma Advanced Research Company Ltd (SPARC) is the listed R&D spin-off of Sun Pharma, which has been evaluating several...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Neurological

Skyhawk Looks To Soar With Huntington’s Hope

 
• By 

Oral RNA splicing modulator has gone into a Phase II/III trial

Draig Is All Fired Up To Transform Neuropsychiatric Field

 
• By 

Wales-based group launches with $140m series A.

Supernus Secures Sage With CVR-Supported Deal

 

Supernus agreed to pay $561m upfront plus a contingent value right that could add $234m to buy Sage, topping a previously rejected offer from Biogen.

Who Dares Wins? Roche Moves Parkinson’s Candidate Into Phase III Despite Near Miss

 

Open-label extension data have persuaded Roche to move prasinezumab into Phase III, where it believes a few tweaks to the study design could turn a near miss into success.

More from Therapy Areas

Scholar Rock Shows Muscle-Building PoC In Obesity

 

The company said it intends to maintain a focus on rare neuromuscular disease with apitegromab but could consider partnering in obesity.

Spyre Takes Aim At Roche And J&J In Inflammatory Diseases

 

The US firm was already looking to compete in ulcerative colitis, but now expands its ambitions by moving into rheumatoid arthritis as well.

Draig Is All Fired Up To Transform Neuropsychiatric Field

 
• By 

Wales-based group launches with $140m series A.